Shield结直肠癌筛查测试数据公布后Guardant下降

2025-09-04 20:35

Guardant Health (NASDAQ:GH) lost ~9% in the premarket on Thursday after the company shared data from a clinical trial for its latest colorectal cancer (CRC) screening algorithm (V2) used in its Shield blood test.
The study, an extension of Guardant’s registrational study ECLIPSE, met all primary endpoints, the company said, adding the screening algorithm helped detect 84% of cancers accurately (sensitivity) and correctly returned a negative result 90% of the time (specificity).
Regarding stage I CRC, the V2 algorithm indicated 62% specificity, Guardant (NASDAQ:GH) added. Exact Sciences (NASDAQ:EXAS), the maker of stool-based colorectal cancer screening test Cologuard, added ~3% after the readout.
ECLIPSE data, published in The New England Journal of Medicine, indicated 83% sensitivity for colorectal cancer, one of the co-primary endpoints of the trial, which was designed to test Shield in CRC detection among average-risk adults.

More on Guardant Health, Exact Sciences